Emily J. Gallagher
- ASSISTANT PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Fellowship, Mount Sinai Hospital
Residency, Mount Sinai Hospital
Residency, Internal Medicine
Fellowship, Mater Misericordiae University Hospital
Residency, Mater Misericordiae University Hospital
Internship and Residency, Internal Medicine
MD, University College Dublin
Emily J. Gallagher, MD was appointed as Assistant Professor of Medicine, Endocrinology, Diabetes and Bone Disease in July 2012. Her main interest is in studying the links between obesity, diabetes and cancer, specifically hyperinsulinemia and cancer.
Dr. Gallagher earned her MB BCh BAO (MD equivalent) from University College Dublin, Ireland and then completed internship and residency in internal medicine, followed by fellowship in Endocrinology at the Mater Misericordiae University Hospital, Dublin, Ireland. She completed her postgraduate training at Mount Sinai, where she completed a residency in internal medicine and fellowship in endocrinology. During this time she completed her research training with Dr. Derek LeRoith examining the links between obesity, diabetes and cancer. She was awarded the Endocrine Fellows Foundation, Fellows Development Research Grant in 2010.
Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, LeRoith D. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013 Feb; 32(8).
Ferguson R, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, Leroith D. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2/Neu-mediated breast cancer. Endocrine-related cancer 2013 Apr;.
Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 2012 Jul; 31(27).
Gallagher EJ, Leroith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. The Medical clinics of North America 2011 Sep; 95(5).
Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology 2011 Jul; 152(7).
Gallagher EJ, LeRoith D. Is growth hormone resistance/IGF-1 reduction good for you?. Cell metabolism 2011 Apr; 13(4).
Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends in endocrinology and metabolism: TEM 2010 Oct; 21(10).
Lann D, Gallagher E, Leroith D. Insulin resistance and the metabolic syndrome. Minerva medica 2008 Jun; 99(3).
Via MA, Gallagher EJ, Mechanick JI. Bone physiology and therapeutics in chronic critical illness. Annals of the New York Academy of Sciences 2010 Nov; 1211.
Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. The Mount Sinai journal of medicine, New York; 77(5).
Gallagher EJ, LeRoith D. Insulin, insulin resistance, obesity, and cancer. Current diabetes reports 2010 Apr; 10(2).
Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. Journal of diabetes 2009 Mar; 1(1).
LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2008 Sep; 116 Suppl 1.
Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinology and metabolism clinics of North America 2008 Sep; 37(3).
Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists; 16(5).
Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 2011 Dec; 1243.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Gallagher is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 4 Room AB4-21
1428 Madison Avenue
New York, NY 10029